EXEL Exelixis Inc
Price (delayed)
$36.85
Market cap
$10.31B
P/E Ratio
20.47
Dividend/share
N/A
EPS
$1.8
Enterprise value
$10.29B
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work
Highlights
The company's EPS has surged by 177% YoY and by 14% QoQ
The company's net income has surged by 151% YoY and by 12% QoQ
EXEL's quick ratio is up by 9% year-on-year but it is down by 8% since the previous quarter
Key stats
What are the main financial stats of EXEL
Market
Valuations
Earnings
Shares outstanding
279.88M
Market cap
$10.31B
Enterprise value
$10.29B
Price to earnings (P/E)
20.47
Price to book (P/B)
4.69
Price to sales (P/S)
4.93
EV/EBIT
15.09
EV/EBITDA
13.94
EV/Sales
4.74
Revenue
$2.17B
Gross profit
$2.09B
Operating income
$604.62M
Net income
$521.27M
EBIT
$681.64M
EBITDA
$737.9M
Free cash flow
$671.54M
Per share
Balance sheet
Liquidity
EPS
$1.8
EPS diluted
$1.76
Free cash flow per share
$2.32
Book value per share
$7.86
Revenue per share
$7.48
TBVPS
$9.94
Total assets
$2.95B
Total liabilities
$703.49M
Debt
$190.82M
Equity
$2.24B
Working capital
$1.06B
Debt to equity
0.09
Current ratio
3.63
Quick ratio
3.41
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
34%
Gross margin
96.5%
Net margin
24%
Operating margin
27.9%
Return on assets
18.2%
Return on equity
23.8%
Return on invested capital
28.5%
Return on capital employed
26.8%
Return on sales
31.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXEL stock price
How has the Exelixis stock price performed over time
Intraday
5.02%
1 week
5.29%
1 month
1.15%
1 year
77.85%
YTD
10.66%
QTD
10.66%
Financial performance
How have Exelixis's revenue and profit performed over time
Revenue
$2.17B
Gross profit
$2.09B
Operating income
$604.62M
Net income
$521.27M
Gross margin
96.5%
Net margin
24%
EXEL's operating margin has surged by 200% year-on-year and by 11% since the previous quarter
The company's net income has surged by 151% YoY and by 12% QoQ
The net margin has soared by 111% YoY and by 7% from the previous quarter
The gross profit has grown by 19% YoY and by 4.4% from the previous quarter
Growth
What is Exelixis's growth rate over time
Valuation
What is Exelixis stock price valuation
P/E
20.47
P/B
4.69
P/S
4.93
EV/EBIT
15.09
EV/EBITDA
13.94
EV/Sales
4.74
The company's EPS has surged by 177% YoY and by 14% QoQ
The P/E is 46% below the 5-year quarterly average of 37.6 and 10% below the last 4 quarters average of 22.8
EXEL's P/B is 51% above its 5-year quarterly average of 3.1 and 34% above its last 4 quarters average of 3.5
EXEL's price to sales (P/S) is 30% higher than its last 4 quarters average of 3.8 and 4.9% higher than its 5-year quarterly average of 4.7
The revenue has grown by 18% YoY and by 4.2% from the previous quarter
Efficiency
How efficient is Exelixis business performance
The company's return on equity has surged by 177% YoY and by 12% QoQ
The ROA has soared by 168% YoY and by 12% from the previous quarter
The ROIC has soared by 166% YoY and by 13% from the previous quarter
The company's return on sales has surged by 123% YoY and by 9% QoQ
Dividends
What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXEL.
Financial health
How did Exelixis financials performed over time
EXEL's quick ratio is up by 9% year-on-year but it is down by 8% since the previous quarter
EXEL's current ratio is up by 9% year-on-year but it is down by 8% since the previous quarter
The debt is 91% less than the equity
The company's debt to equity rose by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.